199 related articles for article (PubMed ID: 33719711)
1. Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies.
Ciani O; Grigore B; Blommestein H; de Groot S; Möllenkamp M; Rabbe S; Daubner-Bendes R; Taylor RS
Med Decis Making; 2021 May; 41(4):439-452. PubMed ID: 33719711
[TBL] [Abstract][Full Text] [Related]
2. Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines.
Grigore B; Ciani O; Dams F; Federici C; de Groot S; Möllenkamp M; Rabbe S; Shatrov K; Zemplenyi A; Taylor RS
Pharmacoeconomics; 2020 Oct; 38(10):1055-1070. PubMed ID: 32572825
[TBL] [Abstract][Full Text] [Related]
3. Use of Surrogate end points in HTA.
Mangiapane S; Velasco Garrido M
GMS Health Technol Assess; 2009 Aug; 5():Doc12. PubMed ID: 21289899
[TBL] [Abstract][Full Text] [Related]
4. Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence.
Ciani O; Grigore B; Taylor RS
Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):44-72. PubMed ID: 35608044
[TBL] [Abstract][Full Text] [Related]
5. Surrogate outcomes in health technology assessment: an international comparison.
Velasco Garrido M; Mangiapane S
Int J Technol Assess Health Care; 2009 Jul; 25(3):315-22. PubMed ID: 19619350
[TBL] [Abstract][Full Text] [Related]
6. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports.
Taylor RS; Elston J
Health Technol Assess; 2009 Jan; 13(8):iii, ix-xi, 1-50. PubMed ID: 19203465
[TBL] [Abstract][Full Text] [Related]
7. Surrogate outcomes: experiences at the Common Drug Review.
Rocchi A; Khoudigian S; Hopkins R; Goeree R
Cost Eff Resour Alloc; 2013 Dec; 11(1):31. PubMed ID: 24341379
[TBL] [Abstract][Full Text] [Related]
8. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
Brettschneider C; Lühmann D; Raspe H
GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
[TBL] [Abstract][Full Text] [Related]
9. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
10. Informed decision-making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments.
Weir CJ; Taylor RS
Pharm Stat; 2022 Jul; 21(4):740-756. PubMed ID: 35819121
[TBL] [Abstract][Full Text] [Related]
11. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.
Wang T; McAuslane N; Liberti L; Leufkens H; Hövels A
Value Health; 2018 Jun; 21(6):707-714. PubMed ID: 29909876
[TBL] [Abstract][Full Text] [Related]
12. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
Ball G; Levine MAH; Thabane L; Tarride JE
Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
[TBL] [Abstract][Full Text] [Related]
13. Use of surrogate outcomes in cost-effectiveness models: a review of United Kingdom health technology assessment reports.
Elston J; Taylor RS
Int J Technol Assess Health Care; 2009 Jan; 25(1):6-13. PubMed ID: 19126246
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
16. Adapting Health Technology Assessment agency standards for surrogate outcomes in early stage cancer trials: what needs to happen?
Thorlund K; Shephard C; Machado L; Bourgouin T; Hudson L; Ting E; Dempster W; Bick R
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):331-342. PubMed ID: 38189086
[TBL] [Abstract][Full Text] [Related]
17. Oncology drugs and added benefit: insights from 3 European health technology assessment agencies on the role of efficacy endpoints.
Smith N; Fu AC; Fisher T; Meletiche D; Pawar V
J Med Econ; 2022; 25(1):1-6. PubMed ID: 34809504
[TBL] [Abstract][Full Text] [Related]
18. The impact of HTA reports on health policy: a systematic review.
Gerhardus A; Dintsios CM
GMS Health Technol Assess; 2005 Nov; 1():Doc02. PubMed ID: 21289923
[TBL] [Abstract][Full Text] [Related]
19. Methods of international health technology assessment agencies for economic evaluations--a comparative analysis.
Mathes T; Jacobs E; Morfeld JC; Pieper D
BMC Health Serv Res; 2013 Sep; 13():371. PubMed ID: 24079858
[TBL] [Abstract][Full Text] [Related]
20. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
